Settle down. You should read the last quarterly properly. The...

Settle down. You should read the last quarterly properly.

The last 12 months were cashflow negative, and barely cash flow positive this quarter with 11.4m rev for 12 months. Growth ok, not massive compared to traditional growth stock valuations and it being product based means they'll need much more working capital and marketing cash to achieve future growth.

My point is that It's not worth 105m-110m right now. Remember they only slap their brand on contract manufactured products and have little IP. They're not a Pharma with the associated valuation of a Pharma either.

I'm not saying they won't get there and holding for the ride, it's just definitely priced 2-3 years ahead of itself as who would pay 105m+ for it based on the fundamentals? Given the current market, it's going to be volatile in the short-medium term and it's a long hold in my opinion. Unless it continues to drop then it's a hard road back to 70c+ if they do more capital raises.